
<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  
<!-- Mirrored from investors.scholarrock.com/node/9391/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:08:17 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <title>SEC Filing - Scholar Rock, Inc.</title>
    <meta name="robots" content="noindex">
    <link rel="stylesheet" media="all" href="../../sites/g/files/knoqqb56236/files/css/css_-Ogun-b4Vwq8nD6qwBoEYuBhEF_0grnAaUrH4akFvLUcd37.css?delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl" />

    
    <!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='../../../analytics.imirwin.com/js/container_XFyWYf0m.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WTGMF33');</script>
<!-- End Google Tag Manager -->

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="../../../www.googletagmanager.com/nsca0c.html?id=GTM-WTGMF33"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-sec-filing nir-node--9391 page-template-default page page-parent wp-custom-logo wp-embed-responsive full-width-content genesis-breadcrumbs-visible genesis-singular-image-hidden genesis-footer-widgets-visible top-parent-investors-media investors-media has-no-blocks elementor-default elementor-page cbp-spmenu-push cookies-set cookies-accepted body_classes" id="body" cz-shortcut-listen="true">
      <div class="region region-content">
    <div id="block-nir-pid2662-websitenoticeblock" class="block--website-notice-block block--website-notice-block--9391 block--content--website-notice-block block--content--website-notice-block--9391 block--24a64b1d-13aa-4b20-8029-2df59f99a96c block--24a64b1d-13aa-4b20-8029-2df59f99a96c--9391 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2662-content" class="block--system-main-block block--system-main-block--9391 block--content--system-main-block block--content--system-main-block--9391 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0--9391 block block-system block-system-main-block">
  
    
      <div class="nir-sec-header"><div class="logo"><img src="../../sites/g/files/knoqqb56236/files/Logo.png" alt="Scholar Rock, Inc." />
</div><div class="sec-docs">View:  <div class="field ixbrl-link">
    <a href="ixbrl-viewer"></a>
  </div>
  <div class="file-link">
  <span class="file file--mime-application-rtf file--general"> <a href="../../static-files/0001157523-23-000532.rtf%3b%20filename_%3dUTF-8%27%270001157523-23-000532.rtf" type="application/rtf" title="0001157523-23-000532.rtf">Download DOC</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="../../static-files/0001157523-23-000532.pdf%3b%20filename_%3dUTF-8%27%270001157523-23-000532.pdf" type="application/pdf" title="0001157523-23-000532.pdf">Download PDF</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-vnd-ms-excel file--x-office-spreadsheet"> <a href="../../static-files/0001157523-23-000532.xls%3b%20filename_%3dUTF-8%27%270001157523-23-000532.xls" type="application/vnd.ms-excel" title="0001157523-23-000532.xls">Download XLS</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-octet-stream file--general"> <a href="../../sec-filings/sec-filing/8-k/0001157523-23-000532.html" type="application/octet-stream" title="0001157523-23-000532-ex-101-sch---xbrl-taxonomy-extension-schema.xsd">Download XBRL</a></span><span class="filesize"> </span>
</div>
</div></div>
    <XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srrk="http://scholarrock.com/20230406" xmlns="../../../www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_519c1ffdba27485a88e3520e6cbdc84c" contextRef="c20230406to20230406" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_efe5e420d7154287a5b43e5435911680" contextRef="c20230406to20230406">0001727196</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="#srrk-20230406.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230406to20230406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-06</xbrli:startDate><xbrli:endDate>2023-04-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div>
      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">UNITED







          STATES<br />
          SECURITIES AND EXCHANGE COMMISSION</span><br />
        <span style="font-weight: bold;">Washington, D.C. 20549</span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">FORM







          <ix:nonNumeric name="dei:DocumentType" id="Fact_b8d33857341b4581b83825be49ba478f" contextRef="c20230406to20230406">8-K</ix:nonNumeric></span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">CURRENT REPORT<br />
      </div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      <div>&#160;</div>

      <div style="text-align: center;">Date of Report (Date of earliest event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_a96a426dd15d4503a8c6080142caca46" contextRef="c20230406to20230406" format="ixt:date-monthname-day-year-en">April 6, 2023</ix:nonNumeric></div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_65a37a0e6bdf484cbe7a04d5aca3bab1" contextRef="c20230406to20230406">Scholar Rock Holding Corp</ix:nonNumeric>oration</span><br />
        (Exact Name of Registrant as Specified in Charter)</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_4ba86c93101c41c59010e94a813010bd" contextRef="c20230406to20230406" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_53639e9f325f40d881f5397e85fe9fa8" contextRef="c20230406to20230406">001-38501</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_1ba1a4be38a74cfb884d3104e833f2b6" contextRef="c20230406to20230406">82-3750435</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(I.R.S. Employer Identification Number)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: center;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"> <br />
        </div>

        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_ef69a1b7bd524aa08bdceee7650fd618" contextRef="c20230406to20230406">301 Binney Street</ix:nonNumeric><span style="font-weight: bold;">, </span><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_98a01c4b09a040fc8fd52cfe8b4eefa8" contextRef="c20230406to20230406">3rd Floor</ix:nonNumeric><span style="font-weight: bold;">, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_d397a24dc8534b4c98ce58ba58a53946" contextRef="c20230406to20230406">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_33cf38b92fc64fe0b0dfb110b4adbd21" contextRef="c20230406to20230406">MA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_5b7b5b24063940eca670172d507c22ad" contextRef="c20230406to20230406">02142</ix:nonNumeric></span></div>
<div>
        (Address of Principal Executive Offices) (Zip Code)</div>
</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_8ba0f0492e8c455ba3e9776dcda8d533" contextRef="c20230406to20230406">857</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_4a96dec4e4774a5bb19769043bb2a19f" contextRef="c20230406to20230406">259-3860</ix:nonNumeric></span><br />
        (Registrant&#8217;s telephone number, including area code)</div>

      <div>&#160;</div>

      <div style="text-align: center;">(Former name or former address, if changed since last report)</div>

      <div>&#160;</div>

      <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

      <div>&#160;</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_5eaca00e399c4cf9b411bfa13006b564" contextRef="c20230406to20230406" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;" class="BRFWTab">&#160; </span>Written
        communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_42a7a820dbff4959a5293ad74a68631d" contextRef="c20230406to20230406" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;" class="BRFWTab">&#160; </span>Soliciting
        material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_c62ad3c9857d44cdaf0260f5d5b824f2" contextRef="c20230406to20230406" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;" class="BRFWTab">&#160; </span>Pre-commencement








        communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_461cdf7b24124fdd814885be11e32f47" contextRef="c20230406to20230406" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;" class="BRFWTab">&#160; </span>Pre-commencement








        communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

      <div>&#160;</div>

      <div>Securities registered pursuant to Section 12(b) of the Act:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Trading Symbol(s)</div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_b5b76f779ee1496aa9684c435b9da18b" contextRef="c20230406to20230406">Common Stock, par value $0.001 per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_bd8d902c1c2b4c009880a8464826998b" contextRef="c20230406to20230406">SRRK</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_7ae6ef9fa18e4f3489e06fd6b5bd3297" contextRef="c20230406to20230406" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div>&#160;</div>

      <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging growth company
        <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_dfa7eef1b7564a53a7b0057963bac53b" contextRef="c20230406to20230406" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div>&#160;</div>

      <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
        Act.&#160; <ix:nonNumeric name="dei:EntityExTransitionPeriod" id="Fact_7435bc9290204d70a5a3ac4a8c026a6a" contextRef="c20230406to20230406" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div><span style="font-weight: bold;">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div>

      <div style="font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On April 6, 2023, the Board of Directors (the &#8220;Board&#8221;) of Scholar Rock Holding Corporation (the &#8220;Company&#8221;), upon the recommendation of its Nominating and
        Corporate Governance Committee, increased the size of the Board to ten (10) directors and subsequently appointed Richard Brudnick to join the Board, effective on April 6, 2023, filling the vacancy created by the increase in the size of the Board.
        The Board determined that Mr. Brudnick is independent under the listing standards of NASDAQ and the Company&#8217;s corporate governance guidelines. Mr. Brudnick will serve as a Class III director with a term expiring at the annual meeting of
        stockholders to be held in 2024. In connection with his appointment as a member of the Board, Mr. Brudnick also joined the Audit Committee of the Board (the &#8220;Audit Committee&#8221;), and Kristina Burow stepped off the Audit Committee and no longer serves
        as a member of the Audit Committee.&#160; Following the appointment of Mr. Brudnick, the Company&#8217;s Audit Committee consists of Joshua Reed (Chair), Amir Nashat and Mr. Brudnick. The compositions of the Compensation Committee and the Nominating and
        Corporate Governance Committee remain unchanged. The Board also appointed Srinivas Akkaraju to the Company&#8217;s Science, Innovation and Technology Committee, which now consists of Jeffrey Flier (Chair), Michael Gilman, Akshay Vaishnaw and Dr.
        Akkaraju.</div>

      <div style="font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As a non-employee director, Mr. Brudnick will receive cash compensation and an equity award for his Board service, in accordance with the Company&#8217;s
        non-employee director compensation policy, as amended from time to time. Mr. Brudnick is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or
        understandings between Mr. Brudnick and any other persons pursuant to which he was selected as a director. In addition, Mr. Brudnick will enter into an indemnification agreement with the Company consistent with the form of the existing
        indemnification agreement entered into between the Company and its non-employee directors.</div>

      <div style="font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On April 10, 2023, the Company issued a press release announcing the appointment of Mr. Brudnick to the Board. A copy of this press release is furnished as
        Exhibit 99.1 to this report on Form 8-K.</div>

      <div style="font-size: 10pt;">&#160;</div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01. Financial Statements and Exhibits.</div>

      <div style="font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits</div>

      <div style="font-size: 10pt;">&#160;</div>

      <div style="text-align: left;"><a href="#a53377626ex99_1.htm"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">99.1</span></a><span style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160; </span><a href="#a53377626ex99_1.htm"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Press Release issued by the Company on April 10, 2023, furnished hereto.</span></a></div>

      <div style="font-size: 10pt;">&#160;</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">104</span><span style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160; </span><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data.</span></div>

      <div style="font-size: 10pt;">&#160;</div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div style="font-size: 10pt; text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SIGNATURE<span style="font-family: 'Times New Roman',Times,serif;"><br />
          </span></span><br />
      </div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
        undersigned hereunto duly authorized.</div>

      <div style="font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>

    <td colspan="2" style="vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Scholar Rock Holding Corporation</div>
            </td>

    <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>

    <td style="width: 42%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>

    <td style="width: 42%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Date: April 10, 2023</div>
            </td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">By:</div>
            </td>

    <td style="width: 42%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">/s/ Junlin Ho</div>
            </td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>

    <td style="width: 42%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Junlin Ho</div>
            </td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>

    <td style="width: 42%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">General Counsel &amp; Corporate Secretary</div>
            </td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>

  </tr>


</table>
    </div>

  </div>

</body>

<!-- Mirrored from investors.scholarrock.com/node/9391/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:08:17 GMT -->
</html>
</XBRL>
<div><a name="a53377626ex99_1.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: business wire
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div style="text-align: left;">
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors</b> </h1>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 10, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today
            announced that Richard Brudnick, has been appointed to Scholar Rock&#8217;s Board of Directors as an independent director. Mr. Brudnick is an accomplished biotechnology executive with over three decades of industry experience specializing in the
            corporate development of companies spanning across multiple specialties, stages and therapeutic areas. </p>
          <p> &#8220;We are pleased to welcome Richard to Scholar Rock&#8217;s Board of Directors. Richard brings extensive corporate development experience and leadership acumen, having held several executive positions and currently serving as Chief Business Officer
            of Prime Medicine, which will be instrumental as Scholar Rock advances towards becoming a fully integrated biopharmaceutical company,&#8221; said David Hallal, Chairman of the Board of Scholar Rock. &#8220;As Scholar Rock&#8217;s deep pipeline continues to
            advance, the board and executive leadership team will benefit from Richard&#8217;s decades of broad experience in corporate development and strategy.&#8221; </p>
          <p> &#8220;Scholar Rock has an impressive pipeline with the potential to meaningfully improve the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders and cancer,&#8221; said Mr. Brudnick. &#8220;I am excited to join
            the company&#8217;s Board of Directors, and I look forward to working with the other board members and the leadership team at this pivotal stage.&#8221; </p>
          <p> Mr. Brudnick joined Prime Medicine as Chief Business Officer in July 2022 and is responsible for corporate development and strategy. Prior to Prime, he served as Chief Business Officer and Head of Strategy of Codiak BioSciences, a leader in
            the field of exosome therapeutics. Before joining Codiak, Mr. Brudnick served as Executive Vice President of Business Development and Alliance Management at Bioverativ, where he led business development efforts to build a significant pipeline
            in rare blood disorders. Earlier, Mr. Brudnick spent nearly 15 years at Biogen where he initiated, led and completed transactions that led to several marketed products including Leqembi, Tecfidera, Spinraza and its biosimilars joint venture
            with Samsung. </p>
          <p> Mr. Brudnick holds an M.S. and B.S. in Management Science from Massachusetts Institute of Technology Sloan School of Management. He also serves as a director of InflaRx and Tamarix Pharma. </p>

          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>About Scholar Rock</b> </p>
          <p> Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar
            Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock&#8217;s approach to
            targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular
            level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on
            biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn
            (https://www.linkedin.com/company/scholar-rock/). </p>
          <p> <b>Availability of Other Information About Scholar Rock</b> </p>
          <p> Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange
            Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material
            information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any
            filing under the Securities Act of 1933, as amended. </p>
          <p> Scholar Rock&#174; is a registered trademark of Scholar Rock, Inc. </p>
          <p> <b>Forward-Looking Statements</b> </p>
          <p> This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock&#8217;s future expectations, plans and prospects,
            including without limitation, Scholar Rock&#8217;s expectations regarding its growth, strategy, progress and development timing, the ability of any individual to affect the growth, strategy, and progress of Scholar Rock, and the potential of its
            product candidates and proprietary platform.<i> </i>The use of words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other
            similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could
            cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, Scholar Rock&#8217;s ability to provide the financial support,
            resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock&#8217;s nonclinical and preclinical studies and clinical trials, and Scholar Rock&#8217;s ability to manage expenses
            and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, as well as those risks more fully discussed in the section entitled "Risk
            Factors" in Scholar Rock&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock&#8217;s subsequent filings with the Securities and
            Exchange Commission. Any forward-looking statements represent Scholar Rock&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of
            the release, and Scholar Rock undertakes no duty to update this information unless required by law. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b>Scholar Rock:</b> </p>
          <p> <b>I</b><b>nvestors </b><br>
            Rushmie Nofsinger <br>
            Scholar Rock <br>
            rnofsinger@scholarrock.com <br>
            ir@scholarrock.com<br>
            857-259-5573 </p>
          <p> <b>Media </b><br>
            Teagan White <br>
            Finn Partners <br>
            teagan.white@finnpartners.com <br>
            media@scholarrock.com<br>
            212-583-2729 </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>


  </div>

  </div>

          <script type="text/javascript">var s_CCSWebHostingAccount = "trcgscholarrock";</script>
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/9391\/html","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb56236\/themes\/site\/nir_pid2662"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"user":{"uid":0,"permissionsHash":"4506f7b957b4baf2488ee006e9b884f3b49293f46cfb6e03ffbb15fedba12da4"}}</script>
<script src="../../sites/g/files/knoqqb56236/files/js/js_D31miEwayYNfIODJWy2ump8i_gwklTzvOKq4eFgXiKw4996.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl"></script>
<script src="../../../assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" crossorigin="anonymous" async integrity="sha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf"></script>

  </body>
</html>
